Search academic texts

Information × Registration Number 0223U005805, 0122U000576 , R & D reports Title To study the features of the pathogenesis of lung emphysema in the patients with bronchial asthma who have had a COVID-19 and to work out the technology for their treatment (clinical and experimental studies) popup.stage_title Head Feschenko Yurii I., Доктор медичних наукYashyna Liudmyla O., д.мед.н. Registration Date 31-12-2023 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  Object – 132 patients with post-COVID-19 syndrome (among them 25 patients with asthma); 32 white laboratory rats. Aim – to increase the effectiveness of the treatment of bronchial asthma patients who have had a COVID-19, taking into account the features of the pathogenesis of lung injury and clinical, functional characteristics. Methods – questionnaire, clinical, functional, radiological, laboratory, experimental, statistical. The clinical characteristics of the BA patients who have had a COVID-19 are uncontrolled asthma ((11,2  0,7) ACT points, (2,7  0,1) ACQ points) and quality of life impairment. The functional characteristics are decreased vital capacity; decreased bronchial patency; decreased tolerance to physical activity. It was determined that the use of acyclovir, proteflazid and local sanation therapy for the treatment of patients with asthma who have had COVID-19 and reactivation of chronic Epstein-Barr virus infection allows to achieve an improvement in asthma control from (11,8 ± 0,7) to (19,3 ± 0,7) ACT points and from (2,6 ± 0,1) to (1,2 ± 0,1) ACQ-7 points; improvement of patients' quality of life from (70,2 ± 4,9) to (76,4 ± 3,8) % EQ VAS scale; improvement of the vital capacity from (79,2 ± 3,9) % to (90,4 ± 4,1) %, the forced exhalation volume in 1 second from (64,4 ± 3,8) % to (78,1 ± 3,7) % and the patency of the large, medium and small airways, as well as tolerance to physical activity. It was established that cytoflavin inhibits the free radical oxidation and increases the antioxidant activity in experimental pulmonary emphysema. An algorithm for optimizing basic therapy in asthma patients who have had COVID-19 has been developed, which makes it possible to identify reactivation of EBV infection as the cause of uncontrolled asthma in 70,6 % of patients and achieve clinical effectiveness in 88,3 % and functional effectiveness in 75,0 % of patients. Sphere of application – therapy, pulmonology, allergology. Product Description popup.authors Ignatieva Victoria I Vlasova Nataliya A Halai Liudmyla A Gymeniuk Galyna Lvivna Zvol Inna V Korzhov Vitaly I Kuryk Lesia M Moskalenko Svitlana M Opimakh Svitlana G Parkhomenko Nataliya V Polianska Maryna O Prymushko Nataliya A Feshchenko Yurii I Chumak Irina V popup.nrat_date 2023-12-31 Close